STEMIcathAID vs COAPT Risk Score

STEMIcathAID is a patient recognition, response, and record-keeping system designed to improve outcomes through adherence the American Heart Association’s Mission:Lifeline STEMI guidelines. Early restoration of blood flow to occluded coronary vessels has been shown to significantly improve outcomes for high-risk STEMI patients. STEMIcathAID aims to improve these clinical outcomes by optimizing their treatment following many of the recommendations of the AHA by reducing the time to STEMI recognition, lead acquisition, STEMI identification, notification of the catheterization lab, and reperfusion. There are multiple personnel and steps involved in caring for these high-risk patients. STEMIcathAID takes an algorithmic approach which will enhance the coordination and communication tasks essential to rapid assessment and easy transfer of STEMI patients from the field or outside facility. It will also provide protocols for the EMS or outside hospital provider to identify patients in cardiogenic shock even before their arrival in the catheterization lab. The application will integrate live GPS tracking of the patients alongside the time the alarm was raised prompting the sense of urgency in transferring the patient. Incorporating images, videos, illustrations, and live GPS tracking of the EMS, the design will be subdivided into three main sections: 1. EKG Upload by outside facility or EMS 2. Assessment of Cardiogenic Shock 3. STEMI patient transfer pathway When a medical provider, in the field, other hospital, or outpatient office, suspects STEMI, the provider uploads the EKG by taking a picture of it with their phone. Once the EKG is uploaded, the on-call attending at the PCI-capable facility receives a notification from the application. If the attending believes the patient is experiencing a real STEMI, the pathway is activated. Upon activation, the approximately 10-12 people involved in taking care of the patient are notified so they can begin preparations. Adhering to HIPAA compliance, all users log into the encrypted application and begin to collaborate such aspects as patient vitals, shock information, and emergency vehicle current location and estimated arrival time to the cath lab. Through the optimized communication and collaboration of multiple key players in the STEMI pathway, these time-critical, vulnerable patients can begin treatment promptly.

For educational purposes and for use by medical professionals only. For patients with severe functional mitral regurgitation and symptomatic heart failure (left ventricular ejection fraction between 20-50%) despite best medical therapy. The COAPT Risk Score is a simple risk prediction tool created by combining clinical and echocardiographic variables in patients with heart failure (HF) and moderate-to-severe or severe functional mitral regurgitation (FMR) who remain symptomatic despite maximally tolerated guideline directed medical therapy (GDMT). The COAPT Risk Score provides valuable prognostic information regarding the 2-year risk of death and/or heart failure hospitalization (HFH). The score is derived from the COAPT trial population of patients with HF and moderate-to-severe or severe FMR randomized to treatment with either transcatheter edge-to-edge repair (TEER) with MitraClip plus GDMT or GDMT alone. We can incorporate TEER in the risk score and provide updated 2-year risk of death and/or HFH which can serve as a valuable shared decision-making tool for patients and physicians as well as heart teams while deciding about TEER. Created by a team of subject-matter experts including: the director of The Mount Sinai Hospital cardiac cath lab Dr. Kini, Director of Clinical and Interventional Cardiology at the Mount Sinai Health System Dr Sharma, the Mount Sinai Hospital Surgical Director Dr. Tang, COAPT Principal Investigator Dr. Stone, and COAPT Risk Score publication author Dr. Shah.